Back to top
more

Moleculin Biotech (MBRX)

(Delayed Data from NSDQ)

$4.30 USD

4.30
1,860

-0.05 (-1.15%)

Updated Apr 25, 2024 09:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MBRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Moleculin Biotech, Inc. [MBRX]

Reports for Purchase

Showing records 1 - 20 ( 159 total )

Company: Moleculin Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

04/12/2024

Daily Note

Pages: 11

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Moleculin Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

04/11/2024

Company Report

Pages: 6

AACR Poster Strongly Supports Lack Of Annamycin Cardiotox, New CoM Patent

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 25.00

Research Provided by a Third Party

Company: Moleculin Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

03/25/2024

Company Report

Pages: 6

4Q23: Solid Annamycin Data, Pivotal Trial Starts In 2024, Funded Into 4Q24

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 25.00

Research Provided by a Third Party

Company: Moleculin Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

02/13/2024

Industry Report

Pages: 5

Biotechnology - 36th Annual Roth Conference, Biotechnology Track, March 17-19

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 10.00

Research Provided by a Third Party

Company: Moleculin Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

01/24/2024

Company Report

Pages: 6

Reports Annamycin Clinical Data as of YE23, Outlines 2024 Milestones

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 25.00

Research Provided by a Third Party

Company: Moleculin Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

12/18/2023

Company Report

Pages: 6

Investor Event Highlights Reasons for Annamycin Optimism in AML

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Company: Moleculin Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

12/14/2023

Company Report

Pages: 36

Reaching for the Right Tool, Annamycin; Initiate at Buy With a $3.00 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 35.00

Research Provided by a Third Party

Company: Moleculin Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

12/11/2023

Daily Note

Pages: 5

Mid-Day Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Moleculin Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

12/11/2023

Company Report

Pages: 6

Annamycin Continues Delivering Impressive Efficacy in AML at ASH Meeting

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Company: Moleculin Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

11/13/2023

Daily Note

Pages: 5

Mid-Day Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Moleculin Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

11/13/2023

Company Report

Pages: 6

3Q23: Substantial Progress With Annamycin Trials, Still Funded Into 3Q24

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Company: Moleculin Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

11/06/2023

Daily Note

Pages: 7

Mid-Day Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Moleculin Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

11/06/2023

Company Report

Pages: 5

Incrementally More Phase 2 Data Evaluating Annamycin in STS-LM Patients

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Company: Moleculin Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

09/18/2023

Company Report

Pages: 5

Independent Report Shows Lack of Annamycin Cardiotoxicity

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Company: Moleculin Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

08/11/2023

Daily Note

Pages: 6

Mid-Day Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Moleculin Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

08/11/2023

Company Report

Pages: 6

2Q23: Annamycin Trials Progressing Well, RP2D Determined, Funded Into 3Q24

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Company: Moleculin Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

05/11/2023

Daily Note

Pages: 6

Mid-Day Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Moleculin Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

05/11/2023

Company Report

Pages: 6

1Q23: Annamycin Trials Going Well, Ample 2023 Data Flow, Funded Into 3Q24

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Company: Moleculin Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

05/02/2023

Company Report

Pages: 5

CR in 1st Dose Cohort of Annamycin/Cytarabine in AML, 2nd Cohort Begins

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Company: Moleculin Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

04/19/2023

Daily Note

Pages: 9

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party